Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Everolimus 10Octreotide 7pasireotide 5lanreotide 5gallium Ga 68 dotatate 4lutetium Lu 177 dotatate 3cabozantinib 3Sunitinib 3Nivolumab 3ganitumab 2Temozolomide 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2zimberelimab 1veliparib 1telotristat ethyl 1surufatinib 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoid Tumor × recombinant interferon alpha 2b-like protein × Clear all
NCT02455596 2016-01-05

Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Phase 2 Unknown
20 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡